Complex effects of Eladis drug in the treatment of infectious cough

Infectious diseases of the upper respiratory tract are often accompanied by cough syndrome. Pathogenesis of infectious cough is due to the development of a specific inflammatory process in the respiratory tract, namely MCP inflammation, in which both infectious agents themselves and various components of the inflammatory response can act as triggers of the cough onset. The impact of inflammatory mediators, as well as mechanical irritation of cough receptors by mucus coming from the upper respiratory tract in postnasal drip or sputum from the lower respiratory tract, are major factors in the formation of infectious cough. Inflammation in the airways in acute infections can reduce the sensitivity threshold of the cough receptors of the sensory fibers of the cough reflex arc. MCP inflammation in the respiratory tract results in the formation of hypersensitivity of the cough receptors even to minimal environmental irritants, manifested by coughing attacks and beyond past disease. MCP chemokines play a key role in the initiation and maintenance of an inflammatory response in the airways accompanied by cough. New drug Eladis reduces activity of the inflammatory process in the airways by blocking the activation of MCP chemokines. Eladis has demonstrated high efficacy and safety in the treatment of infectious cough in acute respiratory viral infection (ARVI) and acute bronchitis.